 Accession No.: BL-12-K06692

Department of Pathology
Center for Advanced Molecular Diagnostics Unit Number(s): BWH 199-12-14'
75 Francis Street, Boston, MA 02115 DFCI 569-74-9
Tel (857) 307-1500 Fax (857) 307-1522 :
(Sey) (S87) Patient Name: SHUTTS, JOHN H
Birth Date: 11/13/1947
Age Sex: 64 Year old Male 



 

Specimen Submitted Facility Lab Control Number/MRN Hospital Location

A. Molec Dx Fixed tissue/block DFCI Doctor Office
Received Report Date Procedure Date
3/5/2012 3/5/2012

Physician (s)/Copies to:
THOMAS * “RRAMS 1, L

Test Performed - MDOMAP4_B

Test Description --OncoMap 4

Accession numbers on blocks submitted - BS-12-R02122

Original Pathologic Diagnosis - COLON ADENOCARCINOMA

Original Specimen Collection Date -

Estimated percentage of neoplastic cells in submitted specimen - 70%

CLINICAL DATA:

Clinical Diagnosis:
RESULTS
DNA VARIANTS:

APC c.4285C>T (p.G1nl1429*, p.Q1429*, CAA>TAA), exon 15
TP53 c.817C>T (p.Arg273Cys, p.R273C, CGT>TGT), exon 7

INTERPRETATION:

**To date, there is little published evidence relating these genetic changes
to cancer biology or treatment response precluding the use of this information
for decisions regarding patient management outside the context of clinical
research,

NEGATIVE for following mutations with clinical relevance for this tumor type:
AKT1 p.E17K, BRAF p.V600A, BRAF p.V600D, BRAF p.V600E, BRAF p.V600E, BRAF
p.V600K, BRAF p.V600L, BRAF p.V600L, BRAF p.V600M, BRAF p.V600R, EGFR
p.D770_N77linsN, EGFR p.E746_A750>V, EGFR p.E746_A750del, EGFR p.E746_A750del,
EGFR p.£746_S752>A, EGFR p.E746_8752>V, EGFR p.E746_T751>A, EGFR

THOMAS A. ABRAMS, M.D. CLIA: 22D2040971
DFCI Laboratory Director:
44 Binney Street Dr. Neal Lindeman

BOSTON, MA 02115
 




 

p.E746 T75ldel, EGFR p.E746K, EGFR p.G719A, EGFR p.G719C, EGFR p.G719D, EGFR
p.G7198, EGFR p.1744_A750>VK, EGFR p.L747_A750>P, EGFR p.L747_A750>P, EGFR
p.L747_E749del, EGFR p.L747_P753>Q, EGFR p.L747_P753>S, EGFR p.L747_R748>FP,
EGFR p.L747_8752del, EGFR p.L747_1751>P, EGFR p.L747_T751>S, EGFR
p.L747_T75idel, EGFR p.L858R, EGFR p.L858R, EGFR p.L858R, EGFR p.L861Q, EGFR
p.N771_P772>SVDNR, EGFR p.P772_H773insV, EGFR p.S752_I759del, EGFR p.S768I,
EGFR p.T790M, EGFR p.V769_D770insASV, EGFR p.V769_D770insASV, KRAS p.A146T,
KRAS p.A59T, KRAS p.G12A, KRAS p.G12C, KRAS p.G12D, KRAS p.G12R, KRAS p.G12S,
KRAS p.G12V,.KRAS p.G13A, KRAS p.G13C, KRAS p.G13D, KRAS p.G13R, KRAS p.G13S,
KRAS p.G13V, KRAS p.L19F, KRAS p.L19F, KRAS p.Q22K, KRAS p.Q61E, KRAS p.Q61H,
KRAS p.Q61H,.KRAS p.Q61K, KRAS p.Q61L, KRAS p.Q61P, KRAS p.Q61R

The following assays did not yield satisfactory results:
CDKN2A_W110*, CDKN2A W110*, KIT_P585P, RET_A883F, RET.D631_L633>E

TEST INFORMATION

Background:

Somatic mutations in oncogenes and tumor-suppressor genes contribute to
the pathogenesis and evolution of human cancers. These alterations can provide
prognostic and predictive information and stratify cancers for targeted
therapeutic information.

Method:

We have developed a multiplexed assay to detect somatic mutations in
tumor DNA extracted from fresh, frozen or formalin-fixed paraffin-embedded
samples. The assay OncoMap 4 detects mutations in 472 different loci from 41
cancer genes. DNA is isolated from tissue containing at least 50% tumor nuclei
and analyzed by multiplex PCR amplification of the region containing the
nucleotide variant of interest, an optimized primer extension reaction to
generate allele-specific DNA products, and chip-based mass spectrometry for
separation and analysis of the DNA analytes (Sequenom MassARRAY 4). The 41
genes are: ABL1, AKT1, AKT2, APC, BRAF, CDK4,’ CDKN2A, CSF1R, CTNNB1, EGFR,
ERBB2, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2,
JAK3, KIT, KRAS, MAP2K1, MET, MLH1, MYC, NPM1,°NRAS, PDGFRA, PIK3CA, PIK3R1,
PTEN, RB1, RET, SRC, STK11, TP53, VHL. A full listing of the loci tested can
be found at PCMP or by contacting the Center for Advanced Molecular
Diagnostics (857-307-1500).

These tests were developed and their performance characteristics determined by
the , Brigham and Womenaé€™s Hospital. They
have not been cleared or approved by the U.S. Food and Drug Administration.
The FDA has determined that such clearance or approval is not necessary.

REFERENCES:
